Search

Oral Doublet Misses High Benchmark in Metastatic Breast Cancer - OncologySTAT

Oral Doublet Misses High Benchmark in Metastatic Breast Cancer - OncologySTAT

Simple oral therapy with capecitabine and cyclophosphamide was a popular regimen among women with metastatic breast cancer, but its 36% response rate fell short of the prespecified target of 42% in a single-arm, phase II trial conducted by the Southwest Oncology Group.


.... Patients in the S0430 trial received a median of six cycles of cyclophosphamide 100 mg daily on days 1-14 and then repeated after 1 week off, and capecitabine 1,500 mg twice daily on days 8-21 and then repeated after 1 week off.